We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Idiopathic Pulmonary Fibrosis Registry for Future Studies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2014 by Clay Marsh MD, The Ohio State University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00815711
First Posted: December 30, 2008
Last Update Posted: August 22, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Clay Marsh MD, The Ohio State University
December 29, 2008
December 30, 2008
August 22, 2014
December 2008
January 2015   (Final data collection date for primary outcome measure)
Framework [ Time Frame: 7 + years ]
To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated
Not Provided
Complete list of historical versions of study NCT00815711 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Idiopathic Pulmonary Fibrosis Registry for Future Studies
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis
To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.
To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physiologic measures that follow patients through their course will allow the following proposed studies as well as future investigations to be efficiently carried out.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
blood serum BAL fluid lung biopsy
Non-Probability Sample
primary care clinic
  • Lung Disease, Interstitial
  • Idiopathic Pulmonary Fibrosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
84
January 2015
January 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.

Exclusion Criteria:

  • pregnancy
  • inability to follow study requirements
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00815711
2007H0002
No
Not Provided
Not Provided
Clay Marsh MD, The Ohio State University
Clay Marsh MD
Not Provided
Principal Investigator: Clay B Marsh, MD Ohio State University
Ohio State University
August 2014